The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants

New England Journal of Medicine

Volumn 340, Issue 10, 1999, Pages 773-779

  Muennig, Peter ^a,b   Pallin, Daniel ^b   Sell, Randall L ^b   Chan, Man Suen ^c  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b Columbia Univ Sch of Public Health ^*  (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HOSPITALIZATION; HUMAN; IMMIGRANT; INTESTINE PARASITE; PARASITOSIS; PREVENTIVE MEDICINE; PRIORITY JOURNAL; SCREENING; UNITED STATES;

ALBENDAZOLE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; EMIGRATION AND IMMIGRATION; FECES; HOSPITALIZATION; HUMANS; INTESTINAL DISEASES, PARASITIC; MASS SCREENING; MODELS, ECONOMIC; PREVENTIVE HEALTH SERVICES;

EID: 0033545543     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199903113401006     Document Type: Article

References (52)

1. Statistical yearbook of the immigration and naturalization service, 1996. Washington, D.C.: Immigration and Naturalization Service, 1997.
2. Keystone JS. Imported intestinal parasites: a growing problem? Can Med Assoc J 1981;125:415-6, 450.
3. Persson A, Rombo L. Intestinal parasites in refugees and asylum seekers entering the Stockholm area, 1987-88: evaluation of routine stool screening. Scand J Infect Dis 1994;26:199-207.
4. Gyorkos TW, Frappier Davignon LF, MacLean JD, Viens P. Effect of screening and treatment on imported intestinal parasite infections: results from a randomized, controlled trial. Am J Epidemiol 1989;129:753-61.
5. Barrett-Connor E. Direct dollar costs and savings of screening stool examinations for eggs and parasites in adult Southeast Asian refugees. Am J Trop Med Hyg 1982;31:466-8.
6. Anderson JP, Moser RJ. Parasite screening and treatment among Indochinese refugees: cost-benefit/utility and the General Health Policy Model. JAMA 1985;15:2229-35.
7. Albenza. Philadelphia: SmithKline Beecham Pharmaceuticals, 1997 (package insert).
8. Albonico M, Smith PG, Hall A, Chwaya HM, Alawi KS, Savioli L. A randomized controlled trial comparing mebendazole and albedazole against Ascaris, Trichuris and hookworm infections. Trans R Soc Trop Med Hyg 1994;88:585-9.
9. Rossignol JF, Maisonneuve H. Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis. Trans R Soc Trop Med Hyg 1983;77:707-11.
10. Romero-Cabello R, Robert L, Muñoz-Garcia R, Tanaka J. Estudio aleatorio para comparar seguridad y eficacia de albendazol y metronidazol en el tratamiento de giardiasis en niños. Rev Latinoam Microbiol 1995;37: 315-23.
11. Pungpak S, Bunnag D, Harinasuta T. Albendazole in the treatment of opisthorchiasis and concomitant intestinal helminthic infections. Southeast Asian J Trop Med Public Health 1984;15:44-50.
12. Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Mcd Hyg 1996;55:477-81.
13. Hall A, Nahar Q. Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans R Soc Trop Med Hyg 1993;87:84-6.
14. Archibald LK, Beeching NJ, Gill GV, Bailey JW, Bell DR. Albendazole is effective treatment for chronic strongyloidiasis. QJM 1993;86:191-5.
15. Healthcare Cost and Utilization Project 3 (HCUP-3). Rockville, Md.: Agency for Health Care Policy and Research, 1994 (software).
16. Statewide Planning and Research Cooperative System (SPARCS). Albany: New York State Department of Health, 1996 (software).
17. Claim Detail/Special Reports (CD/SR) System. Albany: New York State Department of Health, Office of Medicaid Management, 1996 (software).
18. Murray CLJ, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries, and risk factors in 1990 and projected to 2020. Vol. 1. Cambridge, Mass.: Harvard School of Public Health, 1996:64-7.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
20. Gilles HM, Ball PAJ, eds. Human parasitic diseases. Vol. 4. Amsterdam: Elsevier, 1991:170.
21. Bureau of the Census. 1990 Census of the population: social and economic characteristics, New York. Vol. 1. Section 1. Washington, D.C.: Department of Commerce, 1993:CP-2-3 (table 168).
22. Guyatt HL, Bundy DA. Estimating prevalence of community morbidity due to intestinal helminths: prevalence of infection as an indicator of the prevalence of disease. Trans R Soc Trop Med Hyg 1991;85:778-82.
23. Grove DI, ed. Strongyloidiasis: a major roundworm infection of man. New York: Taylor and Francis, 1989:218.
24. Salas SD, Heifetz R, Barrett Connor H. Intestinal parasites in Central American immigrants in the United States. Arch Intern Med 1990;150: 1514-6.
25. Buchwald D, Lam M, Hooton TM. Prevalence of intestinal parasites and association with symptoms in Southeast Asian refugees. J Clin Pharm Ther 1995;20:271-5.
26. Medi-Span. Indianapolis: Hearst Data, 1997 (software).
27. Office of Refugee Resettlement. Refugee resettlement program report to the Congress FY 1995. Hyattsville, Md.: Department of Health and Human Services, 1995.
28. MMIS provider manual: Medicaid management information system. Albany: New York State Department of Social Services, 1997.
29. The newest New Yorkers 1990-1994: an analysis of immigration to NYC in the early 1990s. New York: New York City Department of City Planning, 1996:7-8. (Publication no. DCP 96-19.)
30. de Silva NR, Chan MS, Bundy DA. Morbidity and mortality due to ascariasis: re-estimation and sensitivity analysis of global numbers at risk. Trop Med Int Health 1997;2:519-28.
31. Marti H, Koella JC. Multiple stool examinations for ova and parasites and rate of false negative results. J Clin Microbiol 1993;31:3044-5.
32. Sato Y, Kobayashi J, Toma H, Shiroma Y. Efficacy of stool examination for detection of Strongyloides infection. Am J Trop Med Hyg 1995;53: 248-50.
33. Refugee Health Program dataset. Minneapolis: Minnesota Department of Health Refugee Health Program, 1997 (software).
34. Refugee Health Program dataset. Jamaica Plain: Massachusetts Department of Health Refugee and Immigrant Health Program, 1997 (software).
35. Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis 1989;11:755-67.
36. McCaw BR, DeLay P. Demographics and disease prevalence of two new refugee groups in San Francisco: the Ethiopian and Afghan refugees. West J Med 1985;143:271-5.
37. Arfaa F. Intestinal parasites among Indochinese refugees and Mexican immigrants resettled in Contra Costa County, California. J Fam Pract 1981;12:223-6.
38. Catanzaro A, Moser RJ. Health status of refugees from Vietnam, Laos, and Cambodia. JAMA 1982;247:1303-8.
39. Skeels MR, Nims LJ, Mann JM. Intestinal parasitosis among Southeast Asian immigrants in New Mexico. Am J Public Health 1982;72:57-9.
40. Bureau of the Census. 1996 Current population survey. Washington, D.C.: Department of Commerce, 1996 (software).
41. Fernandez EW, Robinson JG. Illustrative ranges of the distribution of undocumented immigrants by state. Bureau of the Census technical working paper no. 8. Washington, D.C.: Bureau of the Census, 1994.
42. Gill GV, Bell DR. Strongyloides stercoralis infection in former Far East prisoners of war. BMJ 1979;2:572-4.
43. Murray CLJ, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from disease, injuries, and risk factors in 1990 and projected to 2020. Vol. 1. Cambridge, Mass.: Harvard School of Public Health, 1996:413.
44. Freedberg KA, Scharfstein JA, Seage GR III, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 279:130-6.
45. Grove DI, ed. Strongyloidiasis: a major roundworm infection of man. New York: Taylor and Francis, 1989:210-1.
46. Pungpak S, Viravan C, Radomyos B, et al. Opisthorchis viverrini infection in Thailand: studies on the morbidity of the infection and resolution following praziquantel treatment. Am J Trop Med Hyg 1997;56:311-4.
47. Allan JC, Velasquez-Tohom M, Fletes C, et al. Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs. Trans R Soc Trop Med Hyg 1997;91:595-8.
48. Schantz PM, Moore AC, Muñoz JL, et al. Neurocysticercosis in an Orthodox Jewish community in New York City. N Engl J Med 1992;327: 692-5.
49. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278:1333-9.
50. Trussed J, Koenig J, Stewart F, Darroch JE. Medical care cost savings from adolescent contraceptive use. Fam Plann Perspect 1997;29:248-55, 295.
51. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA 1997;278:1759-66.
52. Smith S, Weber S, Wiblin T, Nettleman M. Cost-effectiveness of hepatitis A vaccination in healthcare workers. Infect Control Hosp Epidemiol 1997;18:688-91.